Alí Duarte, MD

Rheumatologist @mayoclinic | #Lupus & #APS | Clinical lead, LUMEN💡- Lupus Midwest Network | Tweets my own | 🇲🇽in🇺🇸

[Alí Duarte, MD @AliDuarteMD]

@reumacia @enriquecalvoA Wow, le vas a cambiar la vida.

[José A. Gómez Puerta @DrGomezPuerta]

Advancing the development of criteria for identifying individuals at risk of developing lupus coordinated by
Karen Costenbader
@MartaMartamosca
@AliDuarteMD
@MariaTektonidou and cols
#ELM2026 @SLEuroSociety
#lupus

[Alí Duarte, MD @AliDuarteMD]

@wisit661 @ASNKidney No rheumatologist?!

[Alí Duarte, MD @AliDuarteMD]

@BarjonCar @NatureMedicine Felicidades! Increíble portada

[Alí Duarte, MD @AliDuarteMD]

Grateful to the legendary Sanjeev Sethi for partnering with our team.

[Alí Duarte, MD @AliDuarteMD]

In lupus nephritis (LN), “activity” gets the spotlight—but chronic scarring often decides the long game. So: which chronicity score best predicts outcomes—NIH Chronicity Index (NIH-CI) or the Mayo Clinic Chronicity Score (MCCS)?
https://t.co/eyt9txJqQr

[Alí Duarte, MD @AliDuarteMD]

Bottom line: MCCS and NIH-CI are comparable and add prognostic signal beyond clinical data—with IF/TA doing most of the heavy lifting—and performance was consistent in Class V LN. MCCS may offer a practical edge by aligning chronicity grading across glomerular diseases.